KPX Lifescience.Co.Ltd (114450) — Cash Flow-to-Debt Ratio
KPX Lifescience.Co.Ltd (114450) has a Cash Flow-to-Debt Ratio of 0.22x as of September 2025, meaning its operating cash flow of ₩3.33 Billion could theoretically repay 0% of its total liabilities (₩15.22 Billion) in one year. See KPX Lifescience.Co.Ltd free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
KPX Lifescience.Co.Ltd Cash Flow-to-Debt Ratio (2014–2024)
Historical debt coverage capacity for KPX Lifescience.Co.Ltd across 11 annual periods. Also explore KPX Lifescience.Co.Ltd annual equity growth to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for KPX Lifescience.Co.Ltd (2014–2024)
Year-by-year debt coverage analysis for KPX Lifescience.Co.Ltd. For market capitalisation and broader financial context, see KPX Lifescience.Co.Ltd market cap and net worth.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.06x | ₩525.49 Million | ₩9.22 Billion | ▲ +21.2% |
| 2023 | 0.05x | ₩370.02 Million | ₩7.87 Billion | ▲ +110.1% |
| 2022 | -0.46x | ₩-4.55 Billion | ₩9.79 Billion | ▼ -1292.0% |
| 2021 | 0.04x | ₩611.38 Million | ₩15.68 Billion | ▼ -76.5% |
| 2020 | 0.17x | ₩1.90 Billion | ₩11.48 Billion | ▼ -54.9% |
| 2019 | 0.37x | ₩4.24 Billion | ₩11.54 Billion | ▼ -29.8% |
| 2018 | 0.52x | ₩5.38 Billion | ₩10.26 Billion | ▲ +0.3% |
| 2017 | 0.52x | ₩5.68 Billion | ₩10.87 Billion | ▲ +13.8% |
| 2016 | 0.46x | ₩7.07 Billion | ₩15.39 Billion | ▼ -16.2% |
| 2015 | 0.55x | ₩5.62 Billion | ₩10.25 Billion | ▲ +99.9% |
| 2014 | 0.27x | ₩4.09 Billion | ₩14.90 Billion | — |